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N-methyltransferase activity in humans1–3
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ABSTRACT
Background: Choline is an essential nutrient for humans, and part
of this requirement is met by endogenous synthesis catalyzed by
hepatic phosphatidylethanolamine N-methyltransferase (PEMT).
PEMT activity is difficult to estimate in humans because it requires
a liver biopsy. Previously, we showed that mice that lack functional
PEMT have dramatically reduced concentrations of docosahexae-
noic acid (DHA; 22:6n23) in plasma and of liver phosphatidyl-
choline (PtdCho)—a phospholipid formed by PEMT.
Objective: The objective was to evaluate plasma PtdCho-DHA
concentrations as a noninvasive marker of liver PEMT activity in
humans.
Design: Plasma PtdCho-DHA concentrations were measured in 72
humans before and after they consumed a low-choline diet, and
correlations were analyzed in relation to estrogen status, PEMT
polymorphism rs12325817, the ratio of plasma S-adenosylmethionine
(AdoMet) to S-adenosylhomocysteine (AdoHcy), and dietary cho-
line intake; all of these factors are associated with changes in liver
PEMT activity. PtdCho-DHA and PEMT activity were also mea-
sured in human liver specimens.
Results: At baseline, the portion of PtdCho species containing DHA
(pmol PtdCho-DHA/nmol PtdCho) was higher in premenopausal
women than in men and postmenopausal women (P , 0.01). This
ratio was lower in premenopausal women with the rs12325817
polymorphism in the PEMT gene (P , 0.05), and PtdCho-DHA
concentration and PEMT activity were lower in human liver sam-
ples from women who were homozygous for PEMT rs12325817
(P , 0.05). The ratio of DHA-PtdCho to PtdCho in plasma was
directly correlated with the ratio of AdoMet to AdoHcy (P =
0.0001). The portion of PtdCho species containing DHA in plasma
was altered in subjects who consumed a low-choline diet.
Conclusion: PtdCho-DHA may be useful as a surrogate marker
for in vivo hepatic PEMT activity in humans. This trial was reg-
istered at clinicaltrials.gov as NCT00065546. Am J Clin Nutr
2011;93:968–74.
INTRODUCTION
Humans develop fatty liver, liver damage, and muscle damage
when they consume diets low in choline (1, 2). This nutrient
is obtained in the diet from a wide variety of foods (3–5) and
also can be derived from de novo biosynthesis of phosphati-
dylcholine (PtdCho) in liver (6). This pathway is catalyzed by
phosphatidylethanolamine N-methyltransferase (PEMT), which
utilizes S-adenosylmethionine (AdoMet) to sequentially meth-
ylate phosphatidylethanolamine to form PtdCho. PtdCho is the
most common phospholipid in eukaryotic cellular membranes
and can be hydrolyzed by phospholipase D to release free
choline (6). Most PEMT activity occurs in the liver (7).
Activity of hepatic PEMT is of significant interest because it
can influence the amount of choline that must be obtained from
the diet. We previously reported that individuals with a particular
single nucleotide polymorphism (SNP) in the PEMT gene are at
greater risk of developing liver and muscle dysfunction when
they consume a diet low in choline (8). Moreover, because PEMT
activity is regulated by estrogen in human and mouse hepatocytes
(9–12), the choline requirement is increased for postmenopausal
women (because they have lower estrogen concentrations than do
premenopausal women) (13). Furthermore, knockout mice with
no functional PEMT activity (PEMT 2/2) cannot survive without
adequate choline provided in the diet (14). Many other factors
also can alter PEMT activity, including ethanol (15), certain hy-
polipidemic drugs (16, 17), consumption of a choline-methionine
deficient diet (18, 19), and other SNPs in the PEMT gene (20). In
addition to its influence on dietary choline requirements, pertur-
bations of hepatic PEMT activity also alter the normal secretion
of VLDLs from liver (21–23) and are associated with the de-
velopment of hepatosteatosis (20, 24).
PEMT also may have an important role in fatty acid distri-
bution to tissues. The term PtdCho represents a family of
phospholipids that differ in fatty acid composition but share
a common glycerophosphocholine backbone. PtdCho derived
from the PEMT pathway differs from that generated by the
cytidine diphosphocholine (CDP)–choline pathway. The CDP-
choline pathway forms PtdCho molecules primarily containing
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medium-chain and saturated fatty acids, whereas PtdCho formed by
the PEMT pathway primarily contains long-chain polyunsaturated
fatty acids (PUFAs), such as arachidonic acid (20:4n26) and do-
cosahexaenoic acid (DHA; 22:6n23) (25). The fact that the
phosphatidylethanolamine used by PEMT is rich in DHA, whereas
PtdCho synthesized from choline is not, makes PtdCho-DHA
a good index of PEMT activity. In addition, we previously showed
that PEMT2/2 mice have significantly lower DHA species in
plasma and liver PtdCho than do wild-type mice—an effect not
seen with any other fatty acids (26). In isolated rat hepatocytes,
a rapid increase in PtdCho-DHA concentrations occurred after
treatment with ethanolamine for 2 h, and this increase was pre-
vented when PEMTwas inhibited by 3-deazaadenosine (27), which
also suggests that the PtdCho-DHA concentration is a surrogate
marker for PEMT activity.
Because liver tissue is not easily obtained from human sub-
jects, it has been difficult to assess the activity of hepatic PEMT in
humans. Considering the physiologic importance of PEMT and
its ability to be modulated by many factors, a marker of in vivo
hepatic PEMT activity in humans would be useful. Current
measures of PEMT activity are quite often performed in vitro by
using isolated tissues. In humans, this would require an invasive
liver biopsy and would most likely yield inaccurate results be-
cause in vitro assays cannot replicate the fluctuating substrate and
inhibitor concentrations found in vivo. Therefore, this investi-
gation evaluated the usefulness of assessing plasma PtdCho-DHA




Seventy-two healthy volunteers (20 men and 52 women)
ranging in age from 18 to 70 y were recruited for this study. Subject
enrollment began on 14March 2001 for the first phase of the study
and on 27 June 2007 for the second phase. Of these women, 25
were postmenopausal and 27 were premenopausal. Post-
menopausal status was defined as having had the last spontaneous
menstrual bleeding .12 mo previously and a follicle-stimulating
hormone concentration of .30 IU/L. The details of subject re-
cruitment and the clinical protocol were approved by the In-
stitutional Review Board at the University of North Carolina at
Chapel Hill. The subjects were admitted to the University of
North Carolina at Chapel Hill Clinical and Translational Research
Center where they received specified diets (28) and remained
under the constant supervision of study staff for the entire dura-
tion of the study.
Initially, all participants received a conventional diet of normal
foods containing 550 mg choline/70 kg daily (the current Ade-
quate Intake level; 29), 50 mg betaine/70 kg daily, and 400 dietary
folate equivalents (DFE) daily (baseline). After 10 d of this initial
baseline diet, the subjects entered a choline-depletion phase and
were fed a low-choline diet containing ,50 mg choline/70 kg
daily (with 6 mg betaine/70 kg daily), as confirmed by chemical
analysis of a sample of duplicate food portions (3, 30). All diets
were isocaloric, with 30% of energy from fat, 0.8 g high bio-
logical value protein/kg body weight, and the remaining energy
from carbohydrate. These diets also met or exceeded the Esti-
mated Average Requirement for methionine and cysteine and
the dietary reference intake for all vitamins with the exception
of folate (some of the subjects received 100 lg DFE/d, and
others received 400 lg DFE/d; folate intake did not influence
choline-deficiency organ dysfunction; 1, 8, 31). Periodic meas-
urements of urinary choline and betaine concentrations (30)
were used to confirm compliance with the dietary restrictions
(data not shown). The subjects remained on the depletion diet
until they developed organ dysfunction associated with choline
deficiency or for 42 d if they did not.
The subjects were deemed to have organ dysfunction asso-
ciated with choline deficiency if they had an increase in serum
creatine phosphokinase activity .5-fold (2), an increase in
aspartate aminotransferase .1.5 fold, or an increase in liver fat
(measured by magnetic resonance imaging; 1) of .28% while
consuming the choline-depletion diet. Aspartate aminotrans-
ferase and creatine phosphokinase analyses were performed by
the McClendon Clinical Laboratory at University of North
Carolina Hospitals (Clinical Laboratory Improvement Act and
College of American Pathologists accredited) by using blood
drawn by venipuncture. Additional samples of blood were
collected. After centrifugation, plasma was removed and stored
at 280C until the day of analysis to measure plasma AdoMet,
S-adenosylhomocysteine (AdoHcy), PtdCho, and PtdCho-DHA
concentrations.
Liver tissue procurement
Human liver samples from premenopausal women were
obtained from the Liver Procurement and Distribution System
(University of Minnesota, Minneapolis MN; funded by NIH
contract N01 DK92310). Of the 8 donors, 7 had fatty liver (2 of
which were cirrhotic as well). Synopses of the tissue donors’
medical histories, including the pathologists’ impression di-
agnoses concerning liver fat content, were obtained. The spec-
imens were snap-frozen after removal from the organ donors,
delivered on dry ice, and stored at –80C until analyzed.
Analysis of plasma PtdCho fatty acids
Lipids were extracted from duplicate plasma samples, and
the livers were pulverized in liquid nitrogen by using the
method of Bligh and Dyer (32) in the presence of an internal
standard (1,2-diheptadecanoyl PtdCho; Avanti Polar Lipids,
Alabaster, AL) and 0.02% butylated hydroxytoluene. Lipid
classes were separated by thin-layer chromatography (CHCl3:
MeOH:H2O, 65:30:4, vol:vol), and the PtdCho bands that coe-
luted with authentic standard were collected and saponified, and
the fatty acids were trans-methylated by the sequential addition
of 4.25% NaOH in CHCl3/MeOH (2:1, vol:vol) and 1 N HCl in
saline (33). Fatty acid methyl esters (FAMEs) were separated by
gas chromatography by using a BPX-70 capillary column (SGE,
Austin, TX) and a split injection system (Agilent 7890A Gas
Chromatograph; Agilent Technologies, Santa Clara, CA), with
helium as the carrier gas. The injector temperature was 240C,
and the flame ionization detector 280C. Data were analyzed by
using ChemStation Firmware A.01.09 (Agilent). DHA was
identified and quantified against authentic standards (NuCheck
Prep, Elysian, MN). Data were expressed as pmol PtdCho-DHA/
nmol PtdCho.
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Determination of plasma PtdCho, AdoMet, and AdoHcy
PtdCho was extracted from plasma by the method of Bligh and
Dyer (32). Aqueous and organic compounds were separated,
analyzed, and quantified directly by using liquid chromatogra-
phy/electrospray ionization-isotope dilution mass spectrometry
after the addition of internal standards labeled with stable iso-
topes to correct for recovery (30).
AdoMet and AdoHcy were measured in a subset of plasma
samples from subjects enrolled in 2001–2004 by using an HPLC
method (34). Briefly, 500 lL plasma (in duplicate) was de-
proteinized with trichloroacetic acid, and AdoMet and AdoHcy
were separated by HPLC with the use of a C8 column. Fractions
were collected and derivatized by using naphthalenedialdehyde
and cyanide. The resulting fluorescent isoindoles were sepa-
rated by HPLC with the use of a C18 column and a fluorescence
detector.
PEMT activity assay
Liver homogenates were assayed for PEMT activity by using
a modified method of Ridgway and Vance (35). Briefly, activity
was assessed by using 50 lg protein in 125 mmol Tris-HCl/L
(pH 9.2) and 5 mmol DTT buffer/L (Sigma, St Louis, MO) in
the presence of 200 lmol S-adenosyl-L-methionine/L containing
0.5 lCi S-adenosyl- L-[methyl-3H] methionine (55.70 Ci/mmol;
GE Health Care, Piscataway, NJ) and 0.4 mmol exogenous
phosphatidyldimethylethanolamine/L (P2;Avanti Polar Lipids,
Alabaster, AL). The reaction was carried out for 30 min at 37C
and stopped by adding CHCl3:MeOH:1 N HCl (100:50:1, vol:
vol). An aliquot of the chloroform phase was applied to a silica
gel thin-layer chromatography plate [Si250-PA (19C)-Silica Gel,
Baker Inc, Phillipsburg, NJ ] and developed in CHCl3:MeOH:
acetic acid:H2O (50:30:5:2, vol:vol). Disintegrations per minute
from [3H]-PtdCho were determined in bands that comigrated
with authentic standards by using liquid scintillation spectro-
photometry (Wallac 1410; Pharmacia LKB Nuclear, Gaithers-
burg, MD).
Genotyping
SNP analysis was performed as previously described (8, 13).
Briefly, genomic DNA was extracted from liver tissues by using
TriZol (Invitrogen, Carlsbad, CA) and from peripheral lympho-
cytes isolated from blood by using PureGene (Gentra Systems,
Minneapolis, MN) according to the manufacturer’s instructions.
DNA sequencing was performed on double-stranded DNA tem-
plates obtained from genomic DNA by polymerase chain reaction
(PCR) amplification. Sequencing reactions were performed by the
University of North Carolina at Chapel Hill Genome Analysis
Facility by using a capillary sequencing machine (model 3100;
Applied Biosystems, Foster City, CA). Sequence results were
interpreted by using the program Sequencher (Gene Code Corp,
Ann Arbor, MI). Successful amplification of the 1896–base pair
DNA fragment of the PEMT gene was performed by using Ta-
kara Ex Taq polymerase (Fisher Scientific, Fair Lawn, NJ) with
forward and reverse primers: 5#GAGCACGTGAGCTGT-
CAGTGCCTTTTG3# and 5#CCAACCTCCTTCATACAACA-
GAGGTCC3#, respectively. A 3-step PCR was performed on an
Applied Biosystems 2720 Thermal Cycler under the following
conditions: 96C for 2 min, 30 cycles (94C for 30 s, 60C for 1
min, and 72C for 2 min), extend 72C for 7 min, and soak at 4
C. For the sequence determination of PEMT rs12325817, we used
an additional primer, 5#TAGATTGGTCATGGGAGGCTT3#, to
verify the sequence in a region containing Alu repeats and a poly-
A tail. We also designed forward primers specific to the
rs12325817 allele using GeneFisher (http://bibiserv.techfak.uni-
bielefeld.de/genefisher) so that the SNP would be located at the
3#-end of the priming sequence, which allows for specific PCR
products to be synthesized only if the primer is 100% comple-
mentary to its template DNA. We purchased them from Qiagen
Operon (Huntsville, AL). The PCR reactions were optimized for
each pair of primers, and the products were visualized on a 1.5%
agarose gel to determine the genotype.
Statistical analysis
The effect of sex and menopausal status on the plasma PtdCho-
DHA/PtdCho ratio was determined by mixed-model analysis of
variance by using JMP software (V2; SAS Institute, Cary, NC),
followed by pairwise comparisons of individuals with and
without the PEMT rs12325817 genotype and by dietary treat-
ment after grouping by sex and menopausal status. For the
human liver data, statistical differences in the plasma PtdCho-
DHA/PtdCho ratio and PEMT activity were determined by using
Student’s t test after grouping by genotype. The relation of
plasma AdoMet and AdoHcy concentrations to the plasma
PtdCho-DHA/PtdCho ratio was determined by linear regression
and expressed as the Pearson correlation coefficient. Data are
reported as means 6 SEs, and all results were considered sig-
nificant at P , 0.05.
RESULTS
At baseline, plasma PtdCho-DHA/PtdCho ratios in plasma
were greater in premenopausal women than in men or post-
menopausal women (Figure 1; P , 0.01). This pattern was
maintained when subjects were placed on a low-choline diet
(data not shown). Because PtdCho concentrations were expected
to decrease with choline deficiency, we expressed the data as
a concentration ratio so that PtdCho-DHA could be represented
by the actual amount of PtdCho present. However, we found that
expressing the PtdCho-DHA data as nmol/mL plasma gave
similar results (see Supplemental Figure 1 under “Supplemental
data” in the online issue). The PEMT gene polymorphism
rs12325817 was previously reported to greatly increase the
likelihood of developing organ dysfunction when subjects with
the variant allele consumed a low-choline diet (8), and we sug-
gested that this indicated diminished capacity to form choline
via PEMT activity. In the current study, premenopausal women
homozygous for this SNP had a lower plasma PtdCho-DHA/
PtdCho ratio in plasma than did premenopausal women without
the SNP at baseline (Figure 1; P , 0.05 by t test) and after the
low-choline diet (data not shown). The premenopausal women
with one allele of the SNP had intermediate values (476 4 pmol
PtdCho-DHA/nmol PtdCho; n = 14), which were not statistically
different from those with 2 alleles of the SNP. The plasma
PtdCho-DHA/PtdCho ratio did not differ significantly between
postmenopausal women and men by genotype, including in
those with one allele of the SNP.
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In human livers (n = 8) and plasma (n = 72), ’3% of PtdCho
was present as the DHA species (liver: 2.7 6 0.2 g/100 g fatty
acids; plasma: 3.0 6 0.1 g/100 g fatty acids). Because cirrhotic
livers have fewer hepatocytes and more fibroblasts, we excluded
such livers (n = 2) from our analyses. It is interesting to note that
the cirrhotic livers (both GC genotype) had a lower PtdCho-
DHA content (1.6 6 0.1 g/100 g fatty acids) than did the other
GG/GC samples. Samples from premenopausal women homo-
zygous for the variant allele (CC genotype) had significantly less
PtdCho-DHA than did samples from women with the other
genotypes (Figure 2A; P = 0.01). We measured PEMT activity
in the human livers to determine whether there was a correlation
with PtdCho-DHA concentrations. We found that women ho-
mozygous for the SNP had less PEMT activity than did the other
women (Figure 2B; P = 0.008). There was an insufficient sample
size to analyze the GG and GC genotype groups separately.
We previously reported that some subjects, when placed on
a low-choline diet, developed signs of organ dysfunction, whereas
others did not (1). Plasma PtdCho concentration decreased in
premenopausal women and men fed a low-choline diet (Table 1; P
, 0.05 by paired t test). However, only the men who developed
organ dysfunction (n = 14) had significantly lower plasma PtdCho
concentrations (1615 6 70 nmol/mL) than their baseline values
(1950 6 68 nmol/mL; P = 0.0003 by paired t test). The post-
menopausal group did not differ regardless of diet or depletion
status.
A low-choline diet lowered plasma PtdCho-DHA/PtdCho
ratios in premenopausal women (Figure 3). Of these women,
those who developed organ dysfunction with the low-choline
diet had a 24% decrease in the plasma PtdCho-DHA/total
PtdCho ratio from their basal concentration (214 pmol DHA/
nmol PtdCho) compared with 3% (22 pmol DHA/nmol PtdCho)
in those who did not develop organ dysfunction with the deficient
diet (Figure 3; P = 0.023, t test). Men and postmenopausal women
did not experience a change in the plasma PtdCho-DHA/total
PtdCho ratio when they consumed the deficient diet.
AdoMet is a substrate for PEMT, and AdoHcy (a product of
PEMT) inhibits the enzyme. While consuming the low-choline
diet, subjects with the lowest AdoMet/AdoHcy ratios also had the
lowest plasma PtdCho-DHA/PtdCho as determined by linear
regression (Figure 4; r = 0.716, P = 0.0001).
DISCUSSION
We found that plasma PtdCho-DHA/PtdCho ratios in humans
varied in a manner that was consistent with this measure being
a good surrogate marker for in vivo PEMTactivity in liver. PEMT
activity is induced by estrogen (11, 12) in premenopausal women,
and it is expected to be lower in men and postmenopausal
women (who have low estrogen concentrations). We observed that
premenopausal women had the highest plasma PtdCho-DHA/
PtdCho ratios compared with men and postmenopausal women.
FIGURE 1. Mean (6SE) ratios of phosphatidylcholine docosahexaenoic
acid to phosphatidylcholine (PtdCho-DHA/PtdCho) concentrations in plasma
were highest in premenopausal women with no alleles of the rs12325817
single nucleotide polymorphism (SNP) in the PEMT gene. Plasma was ob-
tained from healthy women and men who consumed a standardized diet that
delivered 550 mg choline/70 kg body weight daily for 10 d. At the end of this
period, blood was collected and the portion of PtdCho species containing DHA
(pmol PtdCho-DHA/nmol PtdCho) was measured in plasma by using gas
chromatography as described in Subjects and Methods. DNA was extracted
from peripheral lymphocytes and genotyped for the PEMT SNP rs12325817
as described in Subjects and Methods. Filled bars represent all subjects (n =
20–27 per group), hatched bars represent subjects with no alleles of the PEMT
SNP (6–8 per group), and open bars represent subjects with 2 alleles of the
PEMT SNP (3–5 per group). *,**ANOVA: *P , 0.05, **P , 0.01.
FIGURE 2. Mean (6SE) phosphatidylcholine docosahexaenoic acid
(PtdCho-DHA) concentrations and phosphatidylethanolamine N-
methyltransferase (PEMT) activity in the liver were lower in premenopausal
women who were homozygous for the rs12325817 single nucleotide poly-
morphism (SNP) in the PEMT gene. Snap-frozen human liver samples were
obtained from the Liver Tissue Procurement and Distribution System (Min-
neapolis, MN). Genomic DNA was extracted and genotyped for PEMT
rs12325817. A: Hepatic lipids were extracted, and the portion of PtdCho
species containing DHA was measured by gas chromatography. B: Another
aliquot of liver was homogenized, and PEMT activity was measured as de-
scribed in Subjects and Methods. Filled bars represent subjects with 1 or 2 of
the major G alleles, hatched bars represent subjects who were homozygous
for the SNP. n = 3 per group. **Significantly different from women with the
CC genotype, P  0.01 (t test).
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PEMT uses AdoMet as a methyl donor and is maximally active
at ’200 lmol AdoMet/L. PEMT is inhibited by AdoHcy (36,
37); thus, PEMT activity should be proportional to the AdoMet/
AdoHcy ratio. We found that the AdoMet/AdoHcy ratio measured
in plasma was correlated with PtdCho-DHA/PtdCho ratios in
plasma.
The PEMT SNP rs12325817 marks a haplotype for which the
variant allele is associated with decreased induction of gene
expression by estrogen (12). Premenopausal women with one or
more variant alleles for this SNP are more likely to develop organ
dysfunction when they consumed a low-choline diet (8) because
of their reduced capacity for endogenous synthesis of PtdCho via
PEMT. These women also have diminished plasma PtdCho-
DHA/PtdCho ratios compared with those without this SNP. In
addition, livers from women homozygous for the variant allele
had less PtdCho-DHA and lower PEMT activity than did women
with the major allele. We also observed that cirrhotic livers had
less PtdCho-DHA—a finding we had previously noted between
normal and cirrhotic livers from men (SH Zeisel and K-A da
Costa, unpublished observations, 2006) and which is consistent
with the published report that plasma long-chain fatty acids are
lower in nonalcoholic steatohepatitis patients than in controls (38).
Whereas the plasma PtdCho-DHA/PtdCho ratio at baseline
correlated well with the differences in PEMT activity expected
from estrogen status and genetic polymorphisms, this ratio did
not increase with consumption of the low-choline diet. Indeed,
we report that in premenopausal women, a low-choline diet was
associated with a decrease in the plasma PtdCho-DHA/PtdCho
ratio in subjects who developed organ dysfunction. This was
surprising because rats fed a choline-methionine deficient diet for
3 wk had increased production of PEMT RNA, increased PEMT
protein, and increased PEMT activity (measured in liver
homogenates by using an in vitro assay in which AdoMet was
added to saturating concentrations; 19). However, another study
(18), which administered [1,2-14C]ethanolamine to rats, de-
termined that in vivo PEMT activity decreased in animals fed
a diet deficient in choline and methionine. This decrease in
activity was attributed to the limited availability of the methyl
group donor, AdoMet, coupled with an elevation in AdoHcy
concentrations that occurs during choline deficiency (39). We
suggest that the study using an in vitro assay for PEMT activity
gave a different result because it did not accurately recreate the
substrate/inhibitor concentration balance that was present in
vivo. It is likely that, despite an increase in PEMT protein,
PEMT-catalyzed formation of PtdCho decreases during choline
deficiency. It makes sense that this effect of a low-choline diet is
most apparent in women with estrogen, because men and
postmenopausal women have little estrogen-induced PEMT ac-
tivity that can be lost when substrates become limiting.
When evaluating plasma PtdCho-DHA/PtdCho ratios as
a surrogate marker for PEMT activity, one factor that should be
FIGURE 3. Mean (6SE) ratios of phosphatidylcholine docosahexaenoic
acid to phosphatidylcholine (PtdCho-DHA/PtdCho) concentrations in plasma
in healthy premenopausal women (F), men (M), and postmenopausal women
(P) after consumption of a standardized diet that delivered 550 mg choline/
70 kg body weight daily for 10 d and after consumption of a diet containing
,50 mg choline/70 kg body weight daily for 42 d or until they developed
liver or muscle dysfunction (D) as described in Subjects and Methods. Subjects
who developed signs of organ dysfunction while consuming the low-choline
diet had decreased plasma PtdCho-DHA/PtdCho ratios. Some subjects did not
develop organ dysfunction within 42 d of consuming the low-choline diet
(ND). Blood was collected at the end of each diet phase, and the portion
of PtdCho species containing DHA was measured in plasma by using gas
chromatography as described in Subjects and Methods. Data are expressed
as the difference between the low-choline and baseline values. n in
parentheses. *Significantly different from ND subjects with the same estro-
gen status, P , 0.05 (t test).
FIGURE 4. Ratios of phosphatidylcholine docosahexaenoic acid to phospha-
tidylcholine (PtdCho-DHA/PtdCho) concentrations in plasma correlated
with ratios of plasma S-adenosylmethionine (AdoMet) to S-adenosylhomo-
cysteine (AdoHcy). Healthy volunteers consumed a standardized diet that
delivered 550 mg choline/70 kg body weight daily for 10 d and then con-
sumed a diet containing,50 mg choline/70 kg body weight daily for42 d or
until they developed liver or muscle dysfunction as described in Subjects and
Methods. At the end of this period, blood was collected and the portion of
PtdCho species containing DHA was measured in plasma by using gas
chromatography as described in Subjects and Methods. Plasma AdoMet and
AdoHcy concentrations were measured at the end of the low-choline phase of
the study as described in Subjects and Methods. The correlation was assessed by
using linear regression analysis (P = 0.0001, r = 0.716). n = 41.
TABLE 1
Plasma phosphatidylcholine concentrations in subjects after consumption
of a low-choline diet1
Group Baseline diet Low-choline diet
nmol/mL nmol/mL
Premenopausal women (n = 27) 1742 6 47 1629 6 522
Men (n = 20) 1842 6 63 1574 6 582
Postmenopausal women (n = 25) 1997 6 82 1906 6 69
1 All values are means6 SEs. Healthy volunteers consumed a standard-
ized diet that delivered 550 mg choline/70 kg body weight daily for 10 d
(baseline), followed by a diet containing,50 mg choline/70 kg body weight
daily (low choline) until they developed liver or muscle dysfunction (de-
termined as described in Subjects and Methods) or for 42 d. Blood was
collected at the end of each diet phase, and plasma phosphatidylcholine
concentrations were measured by mass spectrometry as described in Sub-
jects and Methods.
2 Significantly different from the baseline diet, P , 0.05 (paired t test).
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considered is the subject’s diet. The fatty acids in plasma
phospholipids are responsive to changes in dietary fatty acids,
particularly n23 fatty acids (40), and specifically, supplemen-
tation of the diet with DHA increased serum phospholipid DHA
(41). Diet was not a factor in our comparisons because all of the
individuals in our study were maintained on the same defined
diets. However, fat intake varies widely in free-living in-
dividuals, and this may alter PtdCho-DHA concentrations in-
dependently of PEMT activity. Therefore, it is important to
consider dietary intake of DHA in studies in which plasma
PtdCho-DHA/PtdCho ratios are being used as a surrogate for
PEMT activity. Additional studies using DHA supplementation
would be helpful in determining the extent to which dietary
intake of DHA affects plasma PtdCho-DHA/PtdCho ratios and
its usefulness as a marker for hepatic PEMT activity.
Currently, there is no accurate method to measure in vivo
PEMT activity in humans. Methods using radiolabeled etha-
nolamine are inappropriate for use in humans. Liver biopsy, an
invasive procedure, could yield liver tissue with which to de-
termine PEMT activity; however, measurement outside the body
would require the addition of exogenous substrates (such as
AdoMet). If these added substrates are not reflective of the in vivo
substrate concentrations, this approach would yield an inaccurate
measurement of PEMTactivity. Thus, a surrogatemarker for PEMT
activity in vivo, such as plasma PtdCho-DHA/PtdCho ratios, would
be of help in identifying humans with functionally important SNPs
in the PEMT gene. The rs12325817 SNP examined in this study,
which is located in the promoter region of the gene, is very
common—’70% of our subjects had one or more variant alleles
for this polymorphism (8). There may be many more functionally
important SNPs in PEMT because the gene is highly polymorphic;
98 SNPs were found in a group of only 48 Japanese subjects (42).
Identifying other functionally important SNPs in PEMT by mea-
suring plasma PtdCho-DHA/total PtdCho ratios could help us to
refine our understanding of functional SNPs, which may influence
dietary choline requirements in humans.
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